ArticleOncoimmunology2023

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.

Tuba N Gide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.